Billionaire Sam Zell is among a group of savvy investors backing a small North Carolina biotechnology engineering company...
For technical assistance: (855) 688-2575
Traditional disinfectants only offer short-term protection
Harmful germs contribute to some of our most urgent and devastating worldwide health emergencies. These infectious microbes are everywhere, costing the economy $50B+ each year in the US alone.
Disinfectant sprays and wipes are the standard tools in our antimicrobial arsenal, but they only offer temporary protection. Once the surface is dry—as soon as 2 minutes after treatment—it’s subject to recontamination.
In high-traffic areas, recontaminated surfaces can be dangerous or even deadly.
Novalent protects for up to 90 days
Novalent is a US biotechnology firm on a mission to engineer long-lasting antimicrobial protection for surfaces, skin, and clothing. Founded by leading antimicrobial scientists in 1998, our team invested two decades into proprietary, patented research before launching our technology in 2019. The groundbreaking result is a spray-on product that continuously eliminates germs on surfaces for up to 90 days.
Novalent technology is applied to a clean, disinfected surface
Creates an invisible antimicrobial protective layer which continuously kills bacteria after application
Non-toxic and environmentally friendly—certified by the EPA
Lab-tested, FDA-approved surface protectant and hand sanitizer
We have launched two successful products based on our patented technology:
Novalent AM 90-day surface protectant
Novalent Shield+ 24-hour hand sanitizer
Both are made in our Greensboro, NC manufacturing facility, and are available to businesses and consumers in the US and Australia. Our technology has been approved by the US EPA and FDA, and has been independently tested by leading international laboratories.
Novalent Shield+ hand sanitizer is based on the same antimicrobial technology as Novalent AM, and offers distinct advantages over market leaders like Purell:
- Protects against germs for 24 hours
Non-toxic & doesn’t wash off in water
Alcohol-free, doesn’t dry out skin
$7.7M revenue in 2020
In September 2020, Novalent Shield+ was honored as the winner of the prestigious Good Design Award—making ours the first hand sanitizer ever recognized by a design award.
Used by global leaders across industries
Industry giants like PepsiCo, Sabra, and Starbucks are testing and adopting Novalent products as an effective precaution against microbial contamination. Other companies in testing to add Novalent into their standard operating procedures include:
B2B and retail sales channels
We sell our products directly to some of the world’s largest corporations, and direct to consumers through the Novalent e-store. To date, we have shipped more than 100K units through our retail sales channels, with gross margins of 70%+.
We are making ongoing investments into social media marketing, including securing a total reach of over 250K on Instagram through our Novalent ambassador program.
$80B+ annually in global disinfectant spending
Our technology adds value to businesses and institutions spanning countless industries. As a point of reference when considering Novalent’s potential share: the leading food safety and healthcare chemical firm, Ecolab, has a market cap of $40B.
Our opportunities are far and wide, and we’ve only begun to see early adoption.
Unique patent-protected products
Industry standard surface disinfectants and hand sanitizers all suffer from the same limitation: they kill germs on contact, but only last a few minutes. Novalent products protect against germs for far longer than these legacy products.
They also carry other unique advantages, relative to industry-leading products like Purell hand sanitizer:
Backed by world-renowned investors and executives
Our backers include executives associated with major international corporations and financial institutions.
100+ years combined industry experience
Novalent is chaired by Bill Massa, one of the most experienced private equity CEOs in the US. Bill has been a CEO for five private equity-backed companies, and served as Executive Chair and Operating Partner for ten portfolio companies, with combined value in excess of $10B.
The majority of these companies were in the specialty chemicals space, and ranged in size from $20M to over $1B in revenue.
He has been the CEO of portfolio companies of leading private equity firms, including The Blackstone Group and The Carlyle Group, with $650B and $250B AUM, respectively.
Risks of early stage investment. Not an offer to buy or sell securities. This is a long-term speculative illiquid investment. Investment is not FDIC or SiPC insured.
This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.
All funding-portal activities are conducted by OpenDeal Portal LLC doing business as Republic, a funding portal which is registered with the US Securities and Exchange Commission (SEC) as a funding portal (Portal) and is a member of the Financial Industry Regulatory Authority (FINRA). OpenDeal Portal LLC is located at 335 Madison Avenue, 16th Floor, New York, NY 10017, please check out background on FINRA’s Funding Portal page.
All broker-dealer related securities activity is conducted by OpenDeal Broker LLC, an affiliate of OpenDeal Inc. and OpenDeal Portal LLC, and a registered broker-dealer, and member of FINRA | SiPC, located at 1345 Avenue of the Americas, 15th Floor, New York, NY 10105, please check our background on FINRA’s BrokerCheck. Investments in private companies are particularly risky and may result in total loss of invested capital. Past performance of a security or a company does not guarantee future results or returns. Only investors who understand the risks of early stage investment and who meet the Republic's investment criteria may invest. Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.
Certain pages discussing the mechanics and providing educational materials regarding regulation crowdfunding offerings may refer to OpenDeal Broker LLC and OpenDeal Portal LLC collectively as “Republic”, solely for explanatory purposes.
Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC make investment recommendations and no communication, through this Site or in any other medium should be construed as a recommendation for any security offered on or off this investment platform. Investment opportunities posted on this Site are private placements of securities that are not publicly traded, involve a high degree of risk, may lose value, are subject to holding period requirements and are intended for investors who do not need a liquid investment. Past performance is not indicative of future results. Investors must be able to afford the loss of their entire investment. Only qualified investors, which may be restricted to only Accredited Investors or non-U.S. persons, may invest in offerings hosted by OpenDeal Broker.
Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC, nor any of their officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this Site or the use of information on this site. Offers to sell securities can only be made through official offering documents that contain important information about the investment and the issuers, including risks. Investors should carefully read the offering documents. Investors should conduct their own due diligence and are encouraged to consult with their tax, legal and financial advisors.
Investors should verify any issuer information they consider important before making an investment.